On August 7, 2025, Iovance Biotherapeutics, Inc. reported its financial results for the quarter ending June 30, 2025, and announced the appointment of Corleen Roche as the new Chief Financial Officer effective after the upcoming quarterly report. This filing updates investors on significant leadership changes and financial performance.